Vanda Pharmaceuticals (VNDA) Long-Term Deferred Tax (2010 - 2025)

Vanda Pharmaceuticals has reported Long-Term Deferred Tax for 9 years, with the latest figure at $103.1 million in Q3 2025.

• Quarterly Long-Term Deferred Tax rose 29.88% year-over-year to $103.1 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $103.1 million (up 29.88% YoY) and the FY2024 annual result came in at $81.4 million, up 8.59% from the prior year.
• Long-Term Deferred Tax improved to $103.1 million in Q3 2025 per VNDA's latest filing, from $97.1 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $103.1 million in Q3 2025 and troughed at $67.8 million in Q3 2023.
• A 5-year average of $78.4 million and a median of $75.3 million in 2024 frame the typical range for Long-Term Deferred Tax.
• The sharpest annual moves came in 2022 and 2025: Long-Term Deferred Tax slipped 11.89% in 2022, then rose 29.88% in 2025.
• Over 5 years, Long-Term Deferred Tax stood at $74.9 million in 2021, then dropped by 1.12% to $74.0 million in 2022, then grew by 1.3% to $75.0 million in 2023, then grew by 8.59% to $81.4 million in 2024, then climbed by 26.56% to $103.1 million in 2025.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $103.1 million, $97.1 million, and $89.1 million for Q3 2025, Q2 2025, and Q1 2025 respectively.